Literature DB >> 17437122

Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin.

Kaori Sayanagi1, Fumi Gomi, Miki Sawa, Masahito Ohji, Yasuo Tano.   

Abstract

PURPOSE: To report on the clinical features of three cases of polypoidal choroidal vasculopathy (PCV) during long-term follow-up after photodynamic therapy (PDT).
DESIGN: Interventional case reports.
METHODS: Among the participants in the Japanese Age-Related Macular Degeneration Trial (JAT) at our hospital, a PCV was seen in three eyes at baseline on retrospective analysis of indocyanine green angiography (ICGA) using fundus camera. We report the clinical features of these cases during more than 4 years follow-up.
RESULTS: The mean number of PDT treatments was 5.7. Improved visual acuity (VA) and cessation of fluorescein leakage was achieved within 18 months in all eyes; however, subretinal hemorrhage and subfoveal fluid recurred due to new or recurrent PCV. The final VA decreased markedly in two eyes.
CONCLUSIONS: The eyes with PCV, which had been treated successfully with PDT, may have developed new or recurrent PCV during long-term follow-up. Periodical ICGA would be needed to detect abnormal choroidal vascular changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437122     DOI: 10.1007/s00417-007-0582-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography.

Authors:  Fumi Gomi; Miki Sawa; Keiichi Mitarai; Motokazu Tsujikawa; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-09       Impact factor: 3.117

2.  Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration.

Authors:  Ryo Obata; Yasuo Yanagi; Junko Kami; Hidenori Takahashi; Yuji Inoue; Yasuhiro Tamaki
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

3.  Polypoidal choroidal vasculopathy: natural history.

Authors:  Masanobu Uyama; Mitsumasa Wada; Yoshimi Nagai; Takashi Matsubara; Hiroshi Matsunaga; Ichiro Fukushima; Kanji Takahashi; Miyo Matsumura
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

4.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

5.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

6.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.

Authors:  Kenichiro Sho; Kanji Takahashi; Haruhiko Yamada; Mitsumasa Wada; Yoshimi Nagai; Tsuyoshi Otsuji; Maki Nishikawa; Yumiko Mitsuma; Yukari Yamazaki; Miyo Matsumura; Masanobu Uyama
Journal:  Arch Ophthalmol       Date:  2003-10

7.  Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Maddalena Quaranta; Martine Mauget-Faÿsse; Gabriel Coscas
Journal:  Am J Ophthalmol       Date:  2002-08       Impact factor: 5.258

8.  Treatment of polypoidal choroidal vasculopathy with photodynamic therapy.

Authors:  Richard F Spaide; Irene Donsoff; Deborah L Lam; Lawrence A Yannuzzi; Lee M Jampol; Jason Slakter; John Sorenson; K Bailey Freund
Journal:  Retina       Date:  2002-10       Impact factor: 4.256

9.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

10.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors: 
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258

  10 in total
  13 in total

1.  Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

2.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

3.  Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

4.  Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kyu Seop Kim; Won Ki Lee
Journal:  Jpn J Ophthalmol       Date:  2011-06-07       Impact factor: 2.447

5.  Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.

Authors:  Jae Hyung Lee; Won Ki Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-03       Impact factor: 3.117

6.  Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Eriko Akaza; Miho Haruyama
Journal:  Jpn J Ophthalmol       Date:  2013-05-11       Impact factor: 2.447

Review 7.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

8.  Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term results.

Authors:  Yoshinori Mitamura; Masayasu Kitahashi; Mariko Kubota-Taniai; Shuichi Yamamoto
Journal:  Indian J Ophthalmol       Date:  2010 Jul-Aug       Impact factor: 1.848

9.  Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis.

Authors:  Meng Yong; Minwen Zhou; Guohua Deng
Journal:  BMC Ophthalmol       Date:  2015-07-25       Impact factor: 2.209

10.  Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy.

Authors:  Taiichi Hikichi; Makoto Higuchi; Takuro Matsushita; Shoko Kosaka; Reiko Matsushita; Kimitaka Takami; Hideo Ohtsuka; Hirokuni Kitamei; Shoko Shioya
Journal:  Br J Ophthalmol       Date:  2013-02-21       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.